Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Summary

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.

Timeline

Start

2023-08-01

Primary completion

2029-03-19

Completion

2031-03-27

Publications

• Starling N, Elez E, Strickler JH, Benson A, Oki E, Mendez G, Ferreiro R, Lau YL, Kawazoe A, Tian M, Campbell N, Cohen DN, Edwards K, Stjepanovic N, Seligmann JF. A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design. Future Oncol. 2026 Jan;22(2):137-145. doi: 10.1080/14796694.2025.2606910. Epub 2026 Jan 6.

Drugs

Indications